Hosted by the International Society for Stem Cell Research (ISSCR), the ISSCR 2026 Annual Meeting is a premier global conference for stem cell research and regenerative medicine, bringing together leading academic researchers, clinicians, biotech innovators, and industry stakeholders from around the world.

The program showcases the latest advances across stem cell biology, disease modeling, clinical translation, engineering biology, developmental biology, and regenerative medicine, providing a comprehensive view of emerging science and therapeutic applications. ISSCR 2026 features plenary lectures from world-renowned scientists, award presentations recognizing leaders across career stages, concurrent scientific tracks, poster sessions, networking forums, career development panels, and innovation showcases highlighting new technologies and tools.

The meeting is designed to foster collaboration across academia, industry, and healthcare while accelerating the translation of stem cell discoveries into clinical applications. For companies working in cell and gene therapy, regenerative medicine, research tools, manufacturing, or translational medicine, ISSCR offers a valuable opportunity to engage with key opinion leaders, discover emerging trends, and build strategic partnerships within the global stem cell ecosystem.

Date: Jul 08 鈥� 11, 2026
Location: Palais des congr猫s de Montr茅al
Montreal, Quebec, Canada

JOIN US!

Our iPSC services cover off-the-shelf offerings, custom banking, differentiated cells and iPSC manipulation services for cell therapy programs. Our cell lines offer features such as HLA-homozygosity or favorable blood groups, with full regulatory documentation and support, to shorten the runway into clinical studies. Come meet our team to learn more about our comprehensive iPSC offerings.

Complete the form to schedule a meeting with our experts!

SPEAKING ENGAGEMENTS!

Panel Discussion
Date/Time: July 8, 2:15 PM – 3:45 PM ((UTC-04:00) Eastern Time (US & Canada))
Title: Accelerating pathways from iPSC lines to patient cure: Challenges, solutions, and value of global partnerships
Session Chair: Frederic Cedrone, Vice President Corporate Innovation, 探花合集
Panelists:
Ricardo Baptista, Chief Technology Officer, SmartCella
Bo Wiinberg, Chief Business Development Officer, Novo Nordisk Foundation Cellerator
Brock Reeve, Chief Executive Office, Eos BioInnovation

Gregory Russotti, Chief Technology and Manufacturing Officer, Century Therapeutics

Massimiliano Paganelli, Chief Executive Officer, Morphocell Technologies

ABOUT CATALENT

探花合集, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that 探花合集 helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. 探花合集 provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. 探花合集 tailors end-to-end solutions to meet customers鈥� needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, 探花合集 supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.

 

Championing the missions that matter鈩�

Abstract:鈥� Micronization is a proven approach for improving the bioavailability and performance of poorly soluble drug compounds, but its impact extends far beyond particle size reduction alone. This article examines how solid-state properties can influence stability, dissolution, manufacturability, and overall product performance throughout development. Learn why integrating solid-state characterization into particle engineering strategies is essential for reducing development risk, supporting successful scale-up, and ensuring consistent quality from early development through commercial manufacturing.

Abstract:鈥� Particle size plays a critical role in the performance of poorly soluble, highly potent, and inhaled drug products. This article explores how a science-driven micronization strategy can help enhance bioavailability, achieve consistent dose delivery, and accelerate development while maintaining the quality and scalability needed for clinical and commercial success. Learn how specialized particle engineering expertise, robust containment capabilities, and integrated development support can help overcome complex formulation challenges and streamline the path to patients.

Abstract: This case study highlights 探花合集鈥檚 advanced fiber-optic micro-dissolution technology developed at its Nottingham site to overcome limitations of traditional HPLC-based dissolution testing. By using small, biorelevant media volumes and real-time UV monitoring, the approach enables continuous tracking of drug dissolution behavior, including dynamic effects like supersaturation and precipitation. Compared to conventional methods, it reduces API consumption, provides more physiologically relevant data, and supports faster, more informed formulation decisions during early drug development.

Abstract: This case study highlights 探花合集 Nottingham鈥檚 development of a helium-free gas chromatography (GC) solution using nitrogen as an alternative carrier gas. In response to global helium supply challenges, validated methods were created to seamlessly convert helium-based GC methods to nitrogen without compromising analytical performance. By optimizing column dimensions and flow conditions, the approach delivers efficient separations, reliable data, and even faster analysis times. Supported by advanced instrumentation and expert analytical capabilities, 探花合集 enables pharmaceutical companies to maintain continuity in analytical workflows while reducing dependence on helium.鈥�

Abstract: ASAPprime庐 predictive modeling has been integrated into our stability testing workflows to help customers make faster, more informed decisions during oral solid dose development. By combining short-term, high-stress studies with advanced data modeling, we can predict long-term shelf life, assess temperature and moisture sensitivity, and evaluate formulation and packaging options within weeks.鈥�

This international conference and workshop brings together academic, clinical, and industry experts to explore advances in inhalation drug delivery. The program emphasizes innovative therapies, emerging technologies, and collaboration across pharmaceutical and aerosol medicine research.

Date: 09/11/2026 鈥� 09/13/2026
Location: Parma, Italy

JOIN US!

探花合集 Inhalation has the capabilities, expertise, and state-of-the-art facilities to expedite product development, from concept and feasibility studies through commercial manufacture and release testing.

Schedule a meeting with the 探花合集 Inhalation team to discuss how we can partner and help bring your inhaled therapy to market, faster.

ABOUT CATALENT

探花合集, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that 探花合集 helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. 探花合集 provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. 探花合集 tailors end-to-end solutions to meet customers鈥� needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, 探花合集 supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.

 

Championing the missions that matter鈩�

Built with the support of Microsoft using Microsoft AI technologies, Qai鈩� advances 探花合集’s commitment to operational excellence by enhancing efficiency, accuracy and consistency

Tampa, Fla. 鈥� June 16, 2026 鈥� 探花合集, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced the launch of Qai, an enterprise AI tool designed to elevate the best quality management systems and processes across 探花合集鈥檚 network.

Qai, an AI-enabled solution, strengthens quality management system processes鈥攕uch as deviations and complaints鈥攂y harnessing 探花合集鈥檚 enterprise data to accelerate analysis, root cause identification and corrective and preventive action development, while improving consistency and speed. Qai represents the first enterprise AI solution launched at 探花合集, marking a significant step in its broader effort to implement advanced technologies to drive Patient First outcomes.

Key Highlights

• Qai was built with the support of Microsoft using Microsoft AI technologies powered by Microsoft Azure, including Microsoft Foundry with supporting data and analytics capabilities from Microsoft Fabric.
• Qai strengthens quality management system processes鈥攕uch as deviations and complaints鈥攂y harnessing 探花合集鈥檚 enterprise data to accelerate analysis, root cause identification and corrective and preventive action development, while improving consistency and speed.
• The launch of Qai underscores 探花合集鈥檚 continued investment in digital transformation and innovation.

鈥淭he launch of Qai represents an important milestone in how 探花合集 is applying advanced technologies, including AI, across our operations to improve consistency, accelerate insight and enable better decision-making,鈥� said Charlie Lickfold, Chief Technology Officer, 探花合集. 鈥淚nnovative AI solutions like Qai strengthen the quality of our operations and better support the teams delivering critical therapies to patients around the world.鈥�

Qai integrates intelligent, AI-driven insights directly into existing quality workflows, enabling faster and more consistent decision-making. The platform was built with the support of Microsoft using Microsoft AI technologies powered by Azure, including Foundry, with supporting data and analytics capabilities from Fabric. Qai improves root cause analysis to reduce repeat deviations, accelerates high-quality reporting, and minimizes documentation delays, supporting compliance while helping teams focus on delivering greater value to customers and the patients they serve. Qai exemplifies how 探花合集 is responsibly leveraging AI to empower its global teams, reduce complexity and drive measurable operational impact.

鈥淨ai reflects what we see as an important application of AI in life sciences: enhancing already robust data analytics and governance to deliver meaningful patient impact,鈥� said Todd Mersch, General Manager, U.S. Life Sciences and MedTech, Microsoft. 鈥淏y strengthening oversight and consistency across manufacturing processes, Qai supports 探花合集鈥檚 commitment to delivering for customers and the patients they serve, helping to transform lives.鈥�

About AI at 探花合集

As part of its AI journey, 探花合集 continuously seeks to promote the ethical and responsible use of AI. 探花合集 prioritizes transparency, accountability and fairness in all AI initiatives. 探花合集鈥檚 governance framework supports the development and deployment of AI technologies with human oversight and judgment, aligning with company core values and ethical standards. The company continuously strives to mitigate risks and address ethical considerations, in line with its ambition to ensure AI solutions benefit all stakeholders, contribute positively to society and amplify 探花合集鈥檚 mission and Patient First culture.

The launch of Qai underscores 探花合集鈥檚 continued investment in digital transformation and innovation, advancing the capabilities needed to support the evolving demands of pharmaceutical and biotech customers and improve patient outcomes worldwide.

About 探花合集

探花合集, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that 探花合集 helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. 探花合集 provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. 探花合集 tailors end-to-end solutions to meet customers鈥� needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, 探花合集 supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.

Contacts:

Media:
media@catalent.com

Abstract: Liquid nasal drug delivery has evolved from simple local therapies into a highly versatile platform supporting rapid systemic delivery, emergency rescue medications, and emerging CNS鈥憈argeted treatments. As these applications expand, successful development increasingly depends on early, integrated alignment of formulation science, device selection, analytical control, and manufacturing strategy. In this article, 探花合集 experts Dr. Alan Watts and David Wilcox examine the current and emerging nasal delivery landscape and outline critical chemistry, manufacturing, and controls (CMC) considerations across development, scale鈥憉p, and commercial production. Drawing on real鈥憌orld experience, the piece highlights practical strategies to reduce technical risk, support regulatory readiness, and enable robust, scalable liquid nasal drug products.

The CASSS Cell & Gene Therapy Products (CGTP) Symposium brings together leading scientists, regulators, and biopharma professionals to explore the latest advances in cell and gene therapy development. This multi-day program will focus on critical topics such as manufacturing, quality, and regulatory considerations, while fostering open dialogue that helps shape evolving global standards. Through expert presentations, roundtables, and networking opportunities, attendees gain valuable insights into emerging technologies, commercialization challenges, and innovative approaches driving the future of advanced therapeutics.

Date: June 9-11, 2026
Location: Bethesda North Marriott Hotel & Conference Center, Rockville, Maryland
Booth: #2

JOIN US!

Complete the form to schedule a meeting with our experts!

ABOUT CATALENT

探花合集, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that 探花合集 helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. 探花合集 provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. 探花合集 tailors end-to-end solutions to meet customers鈥� needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, 探花合集 supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.

 

Championing the missions that matter鈩�